Latest Conference Articles

Ghada Abukuwaik, RPh, of Curemed Pharmacy in Clifton, NJ, was awarded the 2019 NCPA Innovation Center Outstanding Adherence Practitioner Award in recognition of her commitment to improving medication adherence. The award is sponsored by RxSafe and was presented at the National Community Pharmacists Association’s 2019 Annual Convention in San Diego.

At the ESMO Congress 2019, Eileen O'Reilly, MD, from Memorial Sloan Kettering Cancer Center, discussed the common themes among emerging therapies in the advanced pancreatic cancer setting.

Two experts shared best practices for operating a pharmacy convenience packaging service with attendees of the National Community Pharmacists Association (NCPA) 2019 Annual Convention in San Diego, California, on Sunday, October 27.

Making medication synchronization a core tenet of a pharmacy’s business can lead to success.

With the legalization of CBD products in 2018, many questions have emerged, not only on the laws governing these products, but on how to integrate CBD into community pharmacies.

Attendees of a session on operating a long-term-care (LTC) pharmacy received tips on key metrics, technology advancements, and meeting customer needs, during the National Community Pharmacists Association (NCPA) 2019 Annual Convention.

Utilizing many of the skills learned in pharmacy school could help to personalize care and enhance medication delivery for patients, potentially leading to reductions in adverse drug events and health care costs,

Pharmacy Times® and Parata Systems celebrated the winners of the 2019 Next-Generation Pharmacist® Awards yesterday at a ceremony held concurrently with the 2019 NCPA Annual Meeting in San Diego, California.

The National Community Pharmacists Association (NCPA) Annual Convention, which takes place this weekend, October 26-29 in San Diego, California, will provide plenty of opportunities for community pharmacists to delve into a number of educational and informative sessions.

At the ESMO Congress 2019, Sara Tolaney, MD, MPH, of Dana-Farber Cancer Institute, spoke about how a collaborative program between pharmacists and oncology providers at her institution helps prevent medication errors.

Suzy Soliman, PharmD, founder of the Pharmacist Moms Group, discusses how Cardinal Health has supported Women Pharmacist Day.

Certain cancer agents may have drug-food or drug-drug interactions that alter exposure to the medication, resulting in a need for individualized dosing.

Suzy Soliman, PharmD, discusses why October 12 was chosen to recognize Women Pharmacist Day.

Ivosidenib improved progression-free survival with a promising trend toward improved overall survival in patients with IDH1-mutated cholangiocarcinoma.

Apalutamide (Erleada) showed an overall survival benefit in patients with non-metastatic castration-resistant prostate cancer.

A regimen of neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab as monotherapy, led to an increased pathological complete response.

A session at the ESMO Congress 2019 highlighted potential prevention and treatment strategies for life-threatening immunotherapy toxicities in patients with cancer.

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen, discussed the increasing value of precision medicine in oncology and what will be needed to facilitate the use of precision medicine as more agents become available.

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen explained the challenges in identifying and treating TRK fusion cancer in patients.

New data confirm high activity of larotrectinib in pediatric and adult patients with TRK fusion cancer.

With more novel therapies entering the market, costs are on the rise, however, new research suggests that the price tag may not reflect the drug’s clinical value.

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, professor of oncology at the University of Copenhagen, discussed the newly-released clinical data highlighting new overall survival and progression-free survival results for larotrectinib (Vitrakvi, Bayer) in tropomyosin receptor kinase (TRK) fusion cancer.

Treatment with a CDK4/6 inhibitor plus fulvestrant found to improve overall survival in women with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer.

The addition of the immunotherapy pembrolizumab (Keytruda) to standard presurgical chemotherapy improved pathological complete response (pCR) rates for patients with triple-negative breast cancer (TNBC).

A pharmacist and nurse led non-medical prescribing clinic that was focused on side effect management and survivorship support for patients with melanoma helped to improve common every-day pressure seen in a medical day unit and improved overall patient experience.

At the ESMO Congress 2019, Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital, talked about how ovarian cancer treatment has evolved over the years.

The PRIMA study evaluated the efficacy and safety of niraparib therapy after response to platinum-based chemotherapy in patients with newly-diagnosed ovarian cancer.

At the ESMO Congress 2019, Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital, discussed the role of oncology pharmacists in managing the treatment of patients with ovarian cancer.